Hepatitis B: Treatment for the 21st century

Antiviral Chemistry and Chemotherapy

Volumn 8, Issue SUPPL.1, 1997, Pages 77-82

  Bowden, S ^a  

^a VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

Author keywords

Antiviral therapy; Chronic hepatitis B; Famciclovir; Hepatitis B virus; Lamivudine; Vaccination

Indexed keywords

ANTIVIRUS AGENT; FAMCICLOVIR; GANCICLOVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PENCICLOVIR; ALPHA INTERFERON; VIRUS DNA;

ANTIVIRAL ACTIVITY; CHRONIC HEPATITIS; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DUCK; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; VIRUS REPLICATION; WOODCHUCK;

EID: 0031543796     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/09563202970080s615     Document Type: Conference Paper

References (36)

1. Alexander GJM, Brahm J, Fagan EA, Smith HM, Daniels HM, Eddleston ALWF & Williams R (1987) Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection. Lancet ii: 66-69.
2. Aye TT, Bartholomeusz A, Shaw T, Bowden S, Breschkin A, McMillan J, Angus P & Locarnini S (1997) Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. Journal of Hepatology 26: 1148-1153.
3. Brook MG, Karayiannis P & Thomas HC (1989) Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 10: 761-763.
4. Chiou HC, Kumura K, Hu A, Kerns KM & Coen DM (1995) Penciclovir-resistance mutations in the herpes simplex virus DNA polymerase gene. Antiviral Chemistry and Chemotherapy 6: 281-288.
5. Colledge D, Locarnini SA & Shaw T (1997) Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro. Hepatology 26: 216-225.
6. Eron JJ (1996) The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials. AIDS 10(Supplement 5): S11-19.
7. Greenberg HB, Pollard RB, Lutwick LI, Gregory PB, Robinson WS & Merigan TC (1976) Effect of human leukocyte Interferon on hepatitis B virus infection in patients with chronic active hepatitis. New England Journal of Medicine 295: 517-522.
8. Honkoop P, de Man RA, Heijtink RA & Schalm SW (1995) Hepatitis B reactivation after lamivudine. Lancet 346: 1156-1157.
9. Honkoop P, de Man RA, Scholte HR, Zondervan PE, Van Den Berg JW, Rademakers LH & Schalm SW (1997) Effect of lamivudine on morphology and function of mitochondria in patients with chronic hepatitis B. Hepatology 26: 211-215.
10. Kane M (1995) Global programme for control of hepatitis B infection. Vaccine 13 (Supplement 1): S47-S49.
11. Lin E, Luscombe C, Wang YY, Shaw T & Locarnini SA (1996) The guanine nucleoside analog penciclovir is active against chronic duck hepatitis B virus infection in vivo. Antimicrobial Agents and Chemotherapy 40: 413-418.
12. Ling R, Mutimer D, Ahmed M, Boxall EH, Ellas E, Dusheiko GM & Harrison TJ (1996) Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 24: 711-714.
13. Locarnini SA & Gust ID (1988). Hepadnaviridae: hepatitis B virus and the delta virus. In Laboratory Diagnosis of Infectious Diseases. Principles and Practice: II Viral, Rickettsial and Chlaydial Diseases. Edited by EH Lennette, P Halonen & F Murphy. New York: Springler-Verlag, pp. 750-796.
14. Locarnini SA, Guo K, Lucas CR & Gust ID (1989) Inhibition of HBV DNA replication by ganciclovir in patients with AIDS. Lancet ii: 1225-1226.
15. Locarnini SA, Lin E, Luscombe C, Wang YY & Shaw T (1996) Long term therapy with penciclovir controls chronic duck hepatitis B virus infection in vivo. Journal of Hepatology 25(Supplement 1): 78.
16. Lok AS (1992) Natural history and control of perinatally acquired hepatitis B virus. Digestive Diseases 10: 46-52.
17. Lok AS (1994) Treatment of chronic hepatitis B. Journal of Viral Hepatitis 1: 105-124
18. Luscombe C, Pedersen J, Uren E & Locarnini SA (1996) Long-term ganciclovir chemotherapy for congenital duck hepatitis B virus infection in vivo: effect on intrahepatic-viral DNA, RNA and protein expression. Hepatology 24: 766-773.
19. Main J, Brown JL, Howells C, Galassini R, Crossey M, Karayiannis P, Georgiou P, Atkinson G & Thomas HC (1996) A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. Journal of Viral Hepatitis 3: 211-215.
20. Mason WS, Seal G & Summers J (1980) Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus. Journal of Virology 36: 829-836.
21. Maupas P, Goudeau A, Couraget P & Bagtrol P (1976) Immunization against hepatitis B in man. Lancet i: 1367-1370.
22. McAleer WJ, Buynak EB, Maigetter RZ, Wampler DE, Miller WJ & Hilleman MR (1984) Human hepatitis B vaccine from recombinant yeast. Nature 307: 178-180.
23. Perillo RP (1989) Interferon therapy for chronic type B hepatitis: the promise comes of age. Gastronenterology 96: 532-536.
24. Schuurman R, Nijhuis M, Van Leeuwen R, Schipper J, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C, Kwok S, Sninsky J & Boucher CAB (1995) Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). Journal of Infectious Diseases 171: 1411-1419.
25. Shaw T & Locarnini SA (1995) Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitis. Liver 15: 169-184.
26. Styrt BA, Piazza-Hepp TD & Chikami GK (1996) Clinical toxicity and antiretroviral nucleoside analogs. Antiviral Research 31: 121-135.
27. Summers J, Smolec JM & Snyder R (1978) A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. Proceedings of the National Academy of Science, USA 75: 4533-4537.
28. Summers J & Mason WS (1982) Replications of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 29: 403-415.
29. Szmuness W, Stevens CE, Zang EA, Harley EJ & Kellner A (1981) A controlled clinical trial of the efficacy of the hepatitis B vaccine (Heptavax B): a final report. Hepatology 1: 377-385.
30. Thomas HC (1988) Hepatitis B viral infection. American Journal of Medicine 85 (Supplement 2a): 135-140.
31. Thomas HC (1995) The emergence of envelope and precore/core variants of hepatitis B virus: the potential role of antibody selection. Journal of Hepatology 22 (Supplement 1): 1-8.
32. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM & Tyrrell DL (1996) Mutations in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 24: 714-717.
33. Trepo C, Jezek, P, Atkinson GF, Boon RJ on behalf of the Famciclovir Chronic Hepatitis Study Group (1996) Efficacy of famciclovir in chronic hepatitis B: results of a dose finding study. Hepotology 24: 247.
34. Wainberg MA, Saloman H, Gu Z, Montaner JS, Cooley TP, McCaffrey R, Ruedy J, Hirst HM, Cammack N, Cameron J & Nicholson W (1995) Development of HIV-1 resistance to (-)2′-deoxy-3′-thiacyidine in patients with AIDS or advanced AIDS-related complex. AIDS 9: 351-357.
35. Zajac BA, West DJ, McAleer WJ & Scolnick EM (1986) Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. Journal of Infection 13A: 39-45.
36. Zuckerman JN (1996) Nonresponse to hepatitis B vaccines and kinetics of anti-HBs production. Journal of Medical Virology 50: 283-288.